Investigational drug · Phase 3
QTORIN 3.9% rapamycin anhydrous
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cutaneous Venous Malformations, Microcystic Lymphatic Malformation.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "QTORIN 3.9% rapamycin anhydrous"
First trial start
2024
Jul 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QTORIN 3.9% rapamycin anhydrous", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cutaneous Venous Malformations
- Microcystic Lymphatic Malformation
Largest trials
Live from ClinicalTrials.gov: studies naming "QTORIN 3.9% rapamycin anhydrous" as an intervention, largest first.
- A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia CongenitaPivotal-lookingCompleted
Palvella Therapeutics, Inc.Industry
NCT05180708 · 87 participants · Start Nov 29, 2021 · Primary completion Jun 30, 2023
Drug: QTORIN 3.9% rapamycin anhydrous gel; Vehicle · For: Pachyonychia Congenita
Sites: Palo Alto, California; New Haven, Connecticut; Orange Park, Florida · 8 sites in all
- SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsPivotal-lookingActive, not recruiting
Palvella Therapeutics, Inc.Industry
NCT06239480 · 51 participants · Start Jul 31, 2024 · Primary completion Jan 14, 2026
Drug: QTORIN 3.9% Rapamycin Anhydrous Gel · For: Microcystic Lymphatic Malformation
Sites: Irvine, California; Palo Alto, California; Atlanta, Georgia · 15 sites in all
- A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPivotal-lookingRecruiting
Palvella Therapeutics, Inc.Industry
NCT05643872 · 45 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 2023
Drug: PTX-022 · For: Pachyonychia Congenita
Sites: New Brighton, Minnesota
- A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsActive, not recruiting
Palvella Therapeutics, Inc.Industry
NCT06653842 · 15 participants (planned) · Start Dec 20, 2024 · Primary completion Nov 21, 2025
Drug: QTORIN 3.9% rapamycin anhydrous gel · For: Cutaneous Venous Malformations
Sites: Irvine, California; Palo Alto, California; Aurora, Colorado · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.